AU2019218319B2 - Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof - Google Patents

Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Info

Publication number
AU2019218319B2
AU2019218319B2 AU2019218319A AU2019218319A AU2019218319B2 AU 2019218319 B2 AU2019218319 B2 AU 2019218319B2 AU 2019218319 A AU2019218319 A AU 2019218319A AU 2019218319 A AU2019218319 A AU 2019218319A AU 2019218319 B2 AU2019218319 B2 AU 2019218319B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019218319A
Other languages
English (en)
Other versions
AU2019218319A1 (en
Inventor
Rudi Bao
Haiqing Hua
Suxia LIU
Ting Wang
Fujun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of AU2019218319A1 publication Critical patent/AU2019218319A1/en
Application granted granted Critical
Publication of AU2019218319B2 publication Critical patent/AU2019218319B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2019218319A 2018-02-11 2019-02-01 Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof Active AU2019218319B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810142118 2018-02-11
CN201810142118.6 2018-02-11
PCT/CN2019/074397 WO2019154315A1 (zh) 2018-02-11 2019-02-01 抗b7-h4抗体、其抗原结合片段及其医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201066A Division AU2026201066A1 (en) 2018-02-11 2026-02-13 Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
AU2019218319A1 AU2019218319A1 (en) 2020-08-13
AU2019218319B2 true AU2019218319B2 (en) 2025-11-13

Family

ID=67548182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019218319A Active AU2019218319B2 (en) 2018-02-11 2019-02-01 Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Country Status (11)

Country Link
US (1) US11472882B2 (https=)
EP (1) EP3753951A4 (https=)
JP (2) JP7393337B2 (https=)
CN (2) CN116693686A (https=)
AU (1) AU2019218319B2 (https=)
BR (1) BR112020015736A2 (https=)
CA (1) CA3089246A1 (https=)
MX (1) MX2020008181A (https=)
TW (1) TWI823895B (https=)
WO (1) WO2019154315A1 (https=)
ZA (1) ZA202004701B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693686A (zh) * 2018-02-11 2023-09-05 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
US20230072897A1 (en) * 2019-06-06 2023-03-09 Shanghai Hansoh Biomedical Co., Ltd. Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
CN115298220B (zh) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
BR112022026508A2 (pt) 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
CN117980332A (zh) * 2020-08-18 2024-05-03 Abl生物公司 抗b7-h4/抗4-1bb双特异性抗体及其应用
MX2023008000A (es) 2021-01-04 2023-07-13 Mersana Therapeutics Inc Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2023283345A1 (en) * 2021-07-07 2023-01-12 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
CA3238965A1 (en) * 2021-12-01 2023-06-08 Kadmon Corporation, Llc B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins
TW202342516A (zh) * 2021-12-23 2023-11-01 愛爾蘭商普羅希那生物科學有限公司 識別分選蛋白的抗體
KR20240163098A (ko) * 2022-03-30 2024-11-18 듀얼리티 바이올로직스 (쑤저우) 컴퍼니 리미티드 B7h4 항체-약물 접합체 및 이의 용도
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
TW202444431A (zh) * 2023-04-12 2024-11-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物在製備預防和／或治療癌症的藥物中的用途

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091580A1 (en) * 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030124140A1 (en) * 1998-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2006104677A2 (en) * 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
WO2009073533A2 (en) * 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20130058864A1 (en) * 2005-03-24 2013-03-07 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
CN103981150A (zh) * 2014-03-28 2014-08-13 苏州大学 抗人b7-h4单克隆抗体及其制备和应用
US20140322129A1 (en) * 2013-03-14 2014-10-30 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN104955475A (zh) * 2012-12-19 2015-09-30 艾普利穆恩公司 抗人b7-h4抗体及其用途
CN105189552A (zh) * 2013-03-14 2015-12-23 基因泰克公司 抗b7-h4抗体和免疫缀合物
WO2016040724A1 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
WO2016160620A2 (en) * 2015-03-27 2016-10-06 University Of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
CN107299085A (zh) * 2017-05-26 2017-10-27 广东医科大学 分泌抗人b7‑h4胞外单克隆抗体杂交瘤细胞株和抗人b7‑h4单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN109563503B (zh) * 2016-07-26 2023-09-29 静冈县 抗b7-h4抗体
CN116693686A (zh) * 2018-02-11 2023-09-05 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
KR20200144094A (ko) * 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124140A1 (en) * 1998-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030091580A1 (en) * 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2006104677A2 (en) * 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US20130058864A1 (en) * 2005-03-24 2013-03-07 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
WO2009073533A2 (en) * 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20110085970A1 (en) * 2007-11-30 2011-04-14 Terrett Jonathan A Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
CN104955475A (zh) * 2012-12-19 2015-09-30 艾普利穆恩公司 抗人b7-h4抗体及其用途
CN105189552A (zh) * 2013-03-14 2015-12-23 基因泰克公司 抗b7-h4抗体和免疫缀合物
US20140322129A1 (en) * 2013-03-14 2014-10-30 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
CN103981150A (zh) * 2014-03-28 2014-08-13 苏州大学 抗人b7-h4单克隆抗体及其制备和应用
WO2016040724A1 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
WO2016160620A2 (en) * 2015-03-27 2016-10-06 University Of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
CN107299085A (zh) * 2017-05-26 2017-10-27 广东医科大学 分泌抗人b7‑h4胞外单克隆抗体杂交瘤细胞株和抗人b7‑h4单克隆抗体及其应用

Also Published As

Publication number Publication date
CA3089246A1 (en) 2019-08-15
US20210032347A1 (en) 2021-02-04
AU2019218319A1 (en) 2020-08-13
JP7393337B2 (ja) 2023-12-06
TW201934581A (zh) 2019-09-01
MX2020008181A (es) 2020-09-18
ZA202004701B (en) 2023-12-20
CN110366560B (zh) 2023-07-28
WO2019154315A1 (zh) 2019-08-15
CN110366560A (zh) 2019-10-22
JP2024026132A (ja) 2024-02-28
BR112020015736A2 (pt) 2020-12-08
CN116693686A (zh) 2023-09-05
TWI823895B (zh) 2023-12-01
EP3753951A4 (en) 2022-03-16
JP2021513331A (ja) 2021-05-27
RU2020124155A (ru) 2022-03-11
US11472882B2 (en) 2022-10-18
EP3753951A1 (en) 2020-12-23
KR20200119846A (ko) 2020-10-20

Similar Documents

Publication Publication Date Title
AU2019218319B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
AU2026201066A1 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
RU2792748C2 (ru) Антитело к b7-h4, его антигенсвязывающий фрагмент и его фармацевтическое применение
KR102952441B1 (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
KR20260053095A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40036076A (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
HK40012331A (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)